Astellas Pharma announced that its license agreement with Janssen Biotech, to develop and commercialize ASP015K, oral Janus Kinase (JAK) inhibitor, will end effective January 15, 2015.
Janssen has exercised its right to terminate the license agreement, which was signed in 2012.
Upon the effective date of termination, Astellas will regain all rights granted to Janssen.
Astellas is now considering the future plan for ASP015K outside Japan, but will continue the Phase 3 development program which was initiated in Japan.
For further deal information visit Current Agreements (subscription required)
Report: Top 50 Big Biotech Partnering and M&A Deal Trends